Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review

T. Kamimura, T. Miyamoto, K. Nagafuji, A. Numata, H. Henzan, K. Takase, Y. Ito, Y. Ohno, T. Fujisaki, T. Eto, Y. Takamatsu, T. Teshima, H. Gondo, K. Akashi, S. Taniguchi, M. Harada

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We retrospectively analyzed the outcomes of 26 patients with acute promyelocytic leukemia (APL) in the first CR (CR1) or second CR (CR2), who underwent autologous PBSCT (auto-PBSCT) between 1992 and 2008. All patients received all-trans retinoic acid-based induction therapy. After two courses of consolidation chemotherapy, upfront auto-PBSCT was performed in 20 patients in the CR1. Five patients had a high WBC count of more than 10 × 10 9/L (high risk), while 15 patients had a count of less than 10 × 109/L (low risk) at initial presentation. In addition, six patients, who were considered as low-risk patients at presentation, had a relapse after three cycles of consolidation and 2 years of maintenance therapy, but gained the molecular remission after re-induction and consolidation, and underwent auto-PBSCT in the CR2. In 26 recipients, engraftment was rapid and no TRM was documented. All 20 patients autotransplanted in CR1 were still in CR at a median of 133 months (73-193 months), and six patients who underwent auto-PBSCT in CR2 were also still in CR at a median of 41 months (2-187 months) without maintenance therapy. PML/RARα chimeric mRNA was undetectable in PBSC or BM samples examined before auto-PBSCT. Despite a small number of cases studied, our retrospective observations suggest that auto-PBSCT may be an effective treatment option to continue durable CR in the treatment of high-risk APL. We review previous reports and discuss the role of autotransplantation in the treatment of APL patients in CR.

Original languageEnglish
Pages (from-to)820-826
Number of pages7
JournalBone Marrow Transplantation
Volume46
Issue number6
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Acute Promyelocytic Leukemia
Autologous Transplantation
Therapeutics
Consolidation Chemotherapy
Tretinoin
Recurrence
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission : Fukuoka BMT Group observations and a literature review. / Kamimura, T.; Miyamoto, T.; Nagafuji, K.; Numata, A.; Henzan, H.; Takase, K.; Ito, Y.; Ohno, Y.; Fujisaki, T.; Eto, T.; Takamatsu, Y.; Teshima, T.; Gondo, H.; Akashi, K.; Taniguchi, S.; Harada, M.

In: Bone Marrow Transplantation, Vol. 46, No. 6, 01.06.2011, p. 820-826.

Research output: Contribution to journalArticle

Kamimura, T, Miyamoto, T, Nagafuji, K, Numata, A, Henzan, H, Takase, K, Ito, Y, Ohno, Y, Fujisaki, T, Eto, T, Takamatsu, Y, Teshima, T, Gondo, H, Akashi, K, Taniguchi, S & Harada, M 2011, 'Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review', Bone Marrow Transplantation, vol. 46, no. 6, pp. 820-826. https://doi.org/10.1038/bmt.2010.207
Kamimura, T. ; Miyamoto, T. ; Nagafuji, K. ; Numata, A. ; Henzan, H. ; Takase, K. ; Ito, Y. ; Ohno, Y. ; Fujisaki, T. ; Eto, T. ; Takamatsu, Y. ; Teshima, T. ; Gondo, H. ; Akashi, K. ; Taniguchi, S. ; Harada, M. / Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission : Fukuoka BMT Group observations and a literature review. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 6. pp. 820-826.
@article{50260e404c824900a9a2bb0297a1bdf7,
title = "Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review",
abstract = "We retrospectively analyzed the outcomes of 26 patients with acute promyelocytic leukemia (APL) in the first CR (CR1) or second CR (CR2), who underwent autologous PBSCT (auto-PBSCT) between 1992 and 2008. All patients received all-trans retinoic acid-based induction therapy. After two courses of consolidation chemotherapy, upfront auto-PBSCT was performed in 20 patients in the CR1. Five patients had a high WBC count of more than 10 × 10 9/L (high risk), while 15 patients had a count of less than 10 × 109/L (low risk) at initial presentation. In addition, six patients, who were considered as low-risk patients at presentation, had a relapse after three cycles of consolidation and 2 years of maintenance therapy, but gained the molecular remission after re-induction and consolidation, and underwent auto-PBSCT in the CR2. In 26 recipients, engraftment was rapid and no TRM was documented. All 20 patients autotransplanted in CR1 were still in CR at a median of 133 months (73-193 months), and six patients who underwent auto-PBSCT in CR2 were also still in CR at a median of 41 months (2-187 months) without maintenance therapy. PML/RARα chimeric mRNA was undetectable in PBSC or BM samples examined before auto-PBSCT. Despite a small number of cases studied, our retrospective observations suggest that auto-PBSCT may be an effective treatment option to continue durable CR in the treatment of high-risk APL. We review previous reports and discuss the role of autotransplantation in the treatment of APL patients in CR.",
author = "T. Kamimura and T. Miyamoto and K. Nagafuji and A. Numata and H. Henzan and K. Takase and Y. Ito and Y. Ohno and T. Fujisaki and T. Eto and Y. Takamatsu and T. Teshima and H. Gondo and K. Akashi and S. Taniguchi and M. Harada",
year = "2011",
month = "6",
day = "1",
doi = "10.1038/bmt.2010.207",
language = "English",
volume = "46",
pages = "820--826",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission

T2 - Fukuoka BMT Group observations and a literature review

AU - Kamimura, T.

AU - Miyamoto, T.

AU - Nagafuji, K.

AU - Numata, A.

AU - Henzan, H.

AU - Takase, K.

AU - Ito, Y.

AU - Ohno, Y.

AU - Fujisaki, T.

AU - Eto, T.

AU - Takamatsu, Y.

AU - Teshima, T.

AU - Gondo, H.

AU - Akashi, K.

AU - Taniguchi, S.

AU - Harada, M.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - We retrospectively analyzed the outcomes of 26 patients with acute promyelocytic leukemia (APL) in the first CR (CR1) or second CR (CR2), who underwent autologous PBSCT (auto-PBSCT) between 1992 and 2008. All patients received all-trans retinoic acid-based induction therapy. After two courses of consolidation chemotherapy, upfront auto-PBSCT was performed in 20 patients in the CR1. Five patients had a high WBC count of more than 10 × 10 9/L (high risk), while 15 patients had a count of less than 10 × 109/L (low risk) at initial presentation. In addition, six patients, who were considered as low-risk patients at presentation, had a relapse after three cycles of consolidation and 2 years of maintenance therapy, but gained the molecular remission after re-induction and consolidation, and underwent auto-PBSCT in the CR2. In 26 recipients, engraftment was rapid and no TRM was documented. All 20 patients autotransplanted in CR1 were still in CR at a median of 133 months (73-193 months), and six patients who underwent auto-PBSCT in CR2 were also still in CR at a median of 41 months (2-187 months) without maintenance therapy. PML/RARα chimeric mRNA was undetectable in PBSC or BM samples examined before auto-PBSCT. Despite a small number of cases studied, our retrospective observations suggest that auto-PBSCT may be an effective treatment option to continue durable CR in the treatment of high-risk APL. We review previous reports and discuss the role of autotransplantation in the treatment of APL patients in CR.

AB - We retrospectively analyzed the outcomes of 26 patients with acute promyelocytic leukemia (APL) in the first CR (CR1) or second CR (CR2), who underwent autologous PBSCT (auto-PBSCT) between 1992 and 2008. All patients received all-trans retinoic acid-based induction therapy. After two courses of consolidation chemotherapy, upfront auto-PBSCT was performed in 20 patients in the CR1. Five patients had a high WBC count of more than 10 × 10 9/L (high risk), while 15 patients had a count of less than 10 × 109/L (low risk) at initial presentation. In addition, six patients, who were considered as low-risk patients at presentation, had a relapse after three cycles of consolidation and 2 years of maintenance therapy, but gained the molecular remission after re-induction and consolidation, and underwent auto-PBSCT in the CR2. In 26 recipients, engraftment was rapid and no TRM was documented. All 20 patients autotransplanted in CR1 were still in CR at a median of 133 months (73-193 months), and six patients who underwent auto-PBSCT in CR2 were also still in CR at a median of 41 months (2-187 months) without maintenance therapy. PML/RARα chimeric mRNA was undetectable in PBSC or BM samples examined before auto-PBSCT. Despite a small number of cases studied, our retrospective observations suggest that auto-PBSCT may be an effective treatment option to continue durable CR in the treatment of high-risk APL. We review previous reports and discuss the role of autotransplantation in the treatment of APL patients in CR.

UR - http://www.scopus.com/inward/record.url?scp=79958139994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958139994&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.207

DO - 10.1038/bmt.2010.207

M3 - Article

C2 - 20818443

AN - SCOPUS:79958139994

VL - 46

SP - 820

EP - 826

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -